Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.

Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS.

AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23.

PMID:
22823027
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: a pilot randomized trial to assess efficacy and safety profile: the KITE study.

Ofotokun I, Sheth AN, Sanford SE, Easley KA, Shenvi N, White K, Eaton ME, Del Rio C, Lennox JL.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1196-206. Epub 2012 Apr 20.

PMID:
22364141
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
[PubMed - indexed for MEDLINE]
4.

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.

MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Hullsiek KH, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M; CPCRA 058 Study Team; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

Lancet. 2006 Dec 16;368(9553):2125-35.

PMID:
17174704
[PubMed - indexed for MEDLINE]
5.

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.

Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group.

J Antimicrob Chemother. 2008 Oct;62(4):797-808. doi: 10.1093/jac/dkn278. Epub 2008 Jul 18.

PMID:
18641035
[PubMed - indexed for MEDLINE]
Free Article
6.

Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.

Lake JE, McComsey GA, Hulgan T, Wanke CA, Mangili A, Walmsley SL, Stramotas SA, Tracy R, Currier JS.

HIV Med. 2014 Aug;15(7):431-41. doi: 10.1111/hiv.12128. Epub 2014 Feb 10.

PMID:
24506429
[PubMed - in process]
7.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team.

N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.

PMID:
25014688
[PubMed - indexed for MEDLINE]
Free Article
8.

Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.

Patel N, Abdelsayed S, Veve M, Miller CD.

Ann Pharmacother. 2011 Mar;45(3):317-24. doi: 10.1345/aph.1P576. Epub 2011 Mar 8.

PMID:
21386025
[PubMed - indexed for MEDLINE]
9.

Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).

Fabbiani M, Mondi A, Colafigli M, D'Ettorre G, Paoletti F, D'Avino A, Ciccarelli N, Sidella L, Murri R, Fortuna S, Vullo V, Cauda R, De Luca A, Di Giambenedetto S.

Scand J Infect Dis. 2014 Jan;46(1):34-45. doi: 10.3109/00365548.2013.840920. Epub 2013 Oct 28.

PMID:
24161018
[PubMed - indexed for MEDLINE]
10.

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA; PIILR Study Group.

AIDS. 2001 Sep 28;15(14):1811-22.

PMID:
11579243
[PubMed - indexed for MEDLINE]
11.

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

Martínez E, Conget I, Lozano L, Casamitjana R, Gatell JM.

AIDS. 1999 May 7;13(7):805-10.

PMID:
10357379
[PubMed - indexed for MEDLINE]
12.

Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.

Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36.

PMID:
11464141
[PubMed - indexed for MEDLINE]
13.

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group.

AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. Erratum in: AIDS. 2010 Oct 23;24(16):2602.

PMID:
20467288
[PubMed - indexed for MEDLINE]
14.

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.

Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, Katlama C, Costagliola D; ANRS 121 Hippocampe study group.

AIDS. 2009 Apr 27;23(7):817-24. doi: 10.1097/QAD.0b013e328328f789.

PMID:
19363330
[PubMed - indexed for MEDLINE]
15.

Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.

Valantin MA, Lanoy E, Bentata M, Kalmykova O, Boutekadjirt A, Allavena C, Rozenbaum W, Peytavin G, Amellal B, Calvez V, Costagliola D, Katlama C; NoNuke ANRS 108 Study Team.

HIV Med. 2008 Oct;9(8):625-35. doi: 10.1111/j.1468-1293.2008.00606.x. Epub 2008 Jul 8.

PMID:
18624724
[PubMed - indexed for MEDLINE]
16.

Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.

Guaraldi G, Zona S, Cossarizza A, Vernacotola L, Carli F, Lattanzi A, Nardini G, Orlando G, Garlassi E, Termini R, Garau M.

Int J STD AIDS. 2014 Mar;25(3):207-12. doi: 10.1177/0956462413497701. Epub 2013 Aug 28.

PMID:
24216034
[PubMed - indexed for MEDLINE]
17.

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL.

AIDS. 2000 Jan 7;14(1):37-49.

PMID:
10714566
[PubMed - indexed for MEDLINE]
18.

A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.

HIV Med. 2005 Sep;6(5):353-9. Erratum in: HIV Med. 2005 Nov;6(6):426.

PMID:
16156884
[PubMed - indexed for MEDLINE]
19.

Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.

Negredo E, Paredes R, Bonjoch A, Tuldrà A, Fumaz CR, Gel S, Garcés B, Johnston S, Arnó A, Balagué M, Jou A, Tural C, Sirera G, Romeu J, Cruz L, Francia E, Domingo P, Arrizabalaga J, Ruiz I, Arribas JR, Ruiz L, Clotet B.

Antivir Ther. 1999;4 Suppl 3:23-8.

PMID:
16021868
[PubMed - indexed for MEDLINE]
20.

A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.

Moyle GJ, Baldwin C, Langroudi B, Mandalia S, Gazzard BG.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):22-8.

PMID:
12792351
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk